Clinical and ethical considerations in pharmacogenetic testing: Views of physicians in 3 "early adopting" departments of psychiatry

Journal of Clinical Psychiatry

Volumn 71, Issue 6, 2010, Pages 745-753

  Hoop, Jinger G ^a   Lapid, Maria I ^b   Paulson, Rene M ^c   Roberts, Laura Weiss ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b MAYO CLINIC   (United States)

^c Elite Research   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CLINICAL PRACTICE; CONFIDENTIALITY; CONSENSUS; COUNSELING; DEPRESSION; DISEASE PREDISPOSITION; DRUG SCREENING; FEMALE; HUMAN; INFORMED CONSENT; MALE; PHARMACOGENETICS; PRIORITY JOURNAL; RISK;

ACADEMIC MEDICAL CENTERS; ATTITUDE OF HEALTH PERSONNEL; CONSENSUS; DEPRESSIVE DISORDER; DRUG TOXICITY; ETHICS, MEDICAL; FEMALE; GENETIC COUNSELING; GENETIC PRIVACY; GENETIC TESTING; HUMANS; INFORMED CONSENT; INTERNET; MALE; PHARMACOGENETICS; PHYSICIAN'S PRACTICE PATTERNS; PHYSICIANS; PSYCHIATRY; QUESTIONNAIRES;

EID: 77953805956     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.08m04695whi     Document Type: Article

References (35)

1. Bradford LD. CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants. Pharmacogenomics. 2002;3(2):229-243.
2. Murphy GM Jr, Hollander SB, Rodrigues HE, et al. Effects of the serotonin transporter gene promoter polymorphism on mirtazapine and paroxetine efficacy and adverse events in geriatric major depression. Arch Gen Psychiatry. 2004;61(11):1163-1169.
3. Serretti A, Kato M, De Ronchi D, et al. Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with selective serotonin reuptake inhibitor efficacy in depressed patients. Mol Psychiatry. 2007;12(3):247-257.
4. Kato M and Serretti A. Review and meta-analysis of antidepressant pharmacogenetic findings in major depressive disorder [published online ahead of print November 4, 2008]. Mol Psychiatry.
5. de Leon J, Armstrong SC, Cozza KL. Clinical guidelines for psychiatrists for the use of pharmacogenetic testing for CYP450 2D6 and CYP450 2C19. Psychosomatics. 2006;47(1):75-85.
6. Kirchheiner J, Brøsen K, Dahl ML, et al. CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants: a first step towards subpopulation-specific dosages. Acta Psychiatr Scand. 2001;104(3):173-192. (Pubitemid 32762271)
7. Hoop JG, Roberts LW, Green Hammond KA, et al. Psychiatrists' attitudes regarding genetic testing and patient safeguards: a preliminary study. Genet Test. 2008;12(2):245-252.
8. Wachbroit R. The question not asked: the challenge of pleiotropic genetic tests. Kennedy Inst Ethics J. 1998;8(2):131-144. (Pubitemid 128447068)
9. Haga SB, Burke W. Pharmacogenetic testing: not as simple as it seems. Genet Med. 2008;10(6):391-395.
10. Hoop JG. Ethical considerations in psychiatric genetics. Harv Rev Psychiatry. 2008;16(6):322-338.
11. Appelbaum PS. Ethical issues in psychiatric genetics. J Psychiatr Pract. 2004;10(6):343-351.
12. Huang CH, Santangelo SL. Autism and serotonin transporter gene polymorphisms: a systematic review and meta-analysis. Am J Med Genet B Neuropsychiatr Genet. 2008;147B(6):903-913.
13. Li D, He L. Meta-analysis supports association between serotonin transporter (5-HTT) and suicidal behavior. Mol Psychiatry. 2007;12(1):47-54. (Pubitemid 44973662)
14. Pascual JC, Soler J, Baiget M, et al. Association between the serotonin transporter gene and personality traits in borderline personality disorder patients evaluated with Zuckerman-Zuhlman Personality Questionnaire (ZKPQ). Actas Esp Psiquiatr. 2007;35(6):382-386.
15. Serretti A, Calati R, Mandelli L, et al. Serotonin transporter gene variants and behavior: a comprehensive review. Curr Drug Targets. 2006;7(12):1659-1669. (Pubitemid 44873728)
16. Bagos PG, Elefsinioti AL, Nikolopoulos GK, et al. The GNB3 C825T polymorphism and essential hypertension: a meta-analysis of 34 studies including 14,094 cases and 17,760 controls. J Hypertens. 2007;25(3):487-500.
17. Kiani JG, Saeed M, Parvez SH, et al. Association of G-protein beta-3 subunit gene (GNB3) T825 allele with Type II diabetes. Neuroendocrinol Lett. 2005;26(2):87-88.
18. Wilkie MJ, Smith D, Reid IC, et al. A splice site polymorphism in the G-protein beta subunit influences antidepressant efficacy in depression. Pharmacogenet Genomics. 2007;17(3):207-215. (Pubitemid 46668005)
19. Lerman C, Jepson C, Wileyto EP, et al. Role of functional genetic variation in the dopamine D2 receptor (DRD2) in response to bupropion and nicotine replacement therapy for tobacco dependence: results of two randomized clinical trials. Neuropsychopharmacology. 2006;31(1):231-242. (Pubitemid 43250960)
20. Sasabe T, Furukawa A, Matsusita S, et al. Association analysis of the dopamine receptor D2 (DRD2) SNP rs1076560 in alcoholic patients. Neurosci Lett. 2007;412(2):139-142. (Pubitemid 46074350)
21. Kirchheiner J, Lang U, Stamm T, et al. Association of CYP2D6 genotypes and personality traits in healthy individuals. J Clin Psychopharmacol. 2006;26(4):440-442. (Pubitemid 44187657)
22. National Human Genome Research Institute. Genetic information nondiscrimination act of 2007. http://www.genome.gov/24519851. Accessed December 10, 2007.
23. Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group. Recommendations from the EGAPP Working Group: testing for cytochrome P450 polymorphisms in adults with nonpsychotic depression treated with selective serotonin reuptake inhibitors. Genet Med. 2007;9(12):819-825.
24. Matchar DB, Thakur ME, Grossman I, et al. Testing for cytochrome P450 polymorphisms in adults with non-psychotic depression treated with selective serotonin reuptake inhibitors (SSRIs). Evid Rep Technol Assess (Full Rep). 2007;(146):1-77.
25. Perlis RH. Pharmacogenetic studies of antidepressant response: how far from the clinic? Psychiatr Clin North Am. 2007;30(1):125-138.
26. Hoop JG, Roberts LW, Green Hammond K, et al. Psychiatrists' attitudes, knowledge, and experience regarding genetics: a preliminary study [published online ahead of print May 16, 2008]. Genet Med.
27. Hoop JG, Salva G, Roberts LW, et al. The current state of genetics training in psychiatric residency: views of 235 U.S. educators and trainees. Acad Psychiatry. 2010;34(2):109-114.
28. Lehrmann JA, Hoop JG, Green Hammond KA, Roberts LW. Medical students' affirmation of ethics education. Acad Psychiatry. 2009;33(6):470-477.
29. Price J, Price D, Williams G, et al. Changes in medical student attitudes as they progress through a medical course. J Med Ethics. 1998;24(2):110-117.
30. Shapiro J, Miller R. How medical students think about ethical issues. Acad Med. 1994;69(7):591-593.
31. Green MJ, Botkin JR. "Genetic exceptionalism" in medicine: clarifying the differences between genetic and nongenetic tests. Ann Intern Med. 2003;138(7):571-575.
32. European Community Huntington's Disease Collaborative Study Group. Ethical and social issues in presymptomatic testing for Huntington's disease: a European Community collaborative study. J Med Genet. 1993;30(12):1028-1035.
33. U.S. Food and Drug Administration Center for Drug Evaluation and Research, Information for Healthcare Professionals: Carbamazepine-FDA Alert. http://www.fda.gov/cder/drug/InfoSheets/HCP/carbamazepineHCP.htm. Accessed 12/30/08.
34. Payne PW Jr. For Asians only? the perils of ancestry-based drug prescribing. J Law Med Ethics. 2008;36(3):585-588.
35. Cook C, Heath F, Thompson RL. A meta-analysis of response rates in web- or internet-based surveys. Educ Psychol Meas. 2000;60(6):821-836.